Multimodality Imaging to Explore Sex Differences in Aortic Stenosis

Gurpreet K Singh [ID][1] and Victoria Delgado [ID][1,2]

1. Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands; 2. Heart Institute, Department of Cardiology, Hospital University Germans Trias i Pujol, Barcelona, Spain

Abstract

The aim of this article is to review sex differences in aortic stenosis (AS) assessed with multimodality imaging. Echocardiography remains the mainstay imaging technique to diagnose AS and provides important insights into the differences between men and women in relation to valve haemodynamic and left-ventricular response. However, echocardiography does not have adequate resolution to provide important insights into sex differences in the degenerative, calcific pathophysiological process of the aortic valve. CT shows that women with AS have more fibrotic changes of the aortic valve whereas men show more calcific deposits. Cardiac magnetic resonance shows that women have left ventricles that are less hypertrophic and smaller compared with those of men, while men have more replacement myocardial fibrosis. These differences may lead to different responses to aortic valve replacement because myocardial diffuse fibrosis but not replacement myocardial fibrosis may regress after the procedure. Sex differences in the pathophysiological process of AS can be assessed using multimodality imaging, assisting in decision-making in these patients.

Aortic stenosis (AS) is the most common valvular heart disease in Western countries, with a prevalence that increases with age.[1–3] Aortic valve calcification (AVC) and fibrosis are the main pathophysiological changes that lead to degenerative AS. However, the relative contribution that each pathophysiological mechanism makes to the development of severe AS differs between men and women. For a similar degree of AS severity, men tend to have higher AVC than women.[4–6] In contrast, women show more valvular fibrosis compared to men.[7] As well as sex differences in the valvular lesion, sex differences in left ventricular (LV) remodelling and myocardial fibrosis in response to AS, have also been reported.[8–10] Men demonstrate more LV systolic dysfunction, impaired LV global longitudinal strain, larger LV mass and volumes and more myocardial fibrosis compared with women. In addition, men show more concentric and eccentric LV hypertrophy, whereas women show more concentric LV remodelling.[11,12] The interplay between the aortic valve lesion and the response of the LV to the pressure overload may differ between men and women and lead to differences in diagnosis rates of severe AS between both sexes. Although echocardiography is the imaging technique of first choice to diagnose severe AS, accurate characterisation of the phenotype of AS in terms of the anatomical lesion, haemodynamic severity and cardiac remodelling response to the pressure overload requires additional imaging techniques such as CT and cardiac magnetic resonance (CMR). These imaging techniques may be helpful in deciding the timing of interventions in patients who have severe AS but are asymptomatic and in patients in whom the diagnosis of the severity of AS is not clear with

echocardiography and when symptoms cannot be explained by other causes (i.e. coronary artery disease and other comorbidities). Furthermore, the use of nuclear imaging techniques has facilitated an understanding of the degeneration process of the aortic valve, which may differ between men and women, and may help to develop medical treatments that will halt the AS degenerative process.

The imaging insights in AS recently reported are summarised in this viewpoint and their implications for clinical management of men and women with severe AS are appraised.

Imaging Sex Differences in the Pathophysiology of Aortic Stenosis

Degenerative AS is mainly caused by the calcification of a tricuspid aortic valve.[13,14] Congenital abnormalities of the aortic valve have been described, the most frequent form being the bicuspid aortic valve, which may also degenerate over time. However, degenerative AS in patients with congenital abnormalities of the aortic valve presents at a younger age and more frequently in men compared with degenerative tricuspid AS.[15,16]

The underlying pathophysiological process of degenerative AS shares similar pathways to those of the coronary atherosclerosis process, but they are not completely identical. The initial changes consist of accumulation and oxidation of lipoproteins in the subendothelium, activation of inflammatory pathways, production of angiotensin-converting

enzyme, up-regulation of adhesion molecules and matrix metalloproteinases and shear stress.[17] Several studies have shown an association between degenerative AS and cardiovascular risk factors, such as diabetes, hypertension, hyperlipidaemia and smoking.[18–20] A recent study in the general population showed a different interaction between sex, cardiovascular risk factors and the development of degenerative AS: while in men, dyslipidaemia was the main factor associated with AVC progression, in women, hypertension was the risk factor associated with AVC progression.[21] Progression of the degenerative process of the aortic valve is followed by alterations in cellular and molecular pathways and in mineral metabolism that leads to leaflet thickening and stiffness. In this phase, oxidised lipoproteins stimulate valvular fibroblasts to release factors that lead to calcific nodule formation.[22] There are also differences between men and women at this stage. For the same degree of severe AS, women show a lower AVC burden compared with men. Aggarwal et al. investigated the association between sex and AVC using ECG-gated non-contrast CT in 665 patients with AS.[4] AVC load was quantified using the Agatston score method. The AVC load in women was lower compared with men (1,703 ± 1,321 arbitrary units [AU] versus 2,694 ± 1,628 AU, respectively). These results have been reproduced in other studies and suggest that women may show more fibrosis of the valve compared with men.[6,7] Using contrast-enhanced CT, Cartlidge et al. showed the possibility of estimating the fibrocalcific ratio of the aortic valve representing the relative contribution of the valve fibrosis and calcification to the AS (*Figure 1*).[23] The fibrocalcific ratio decreased with increasing AS severity and was higher in females than in males, indicating the more important contribution of fibrosis of the valve to AS grade compared with the calcific component in women. Consequently, sex-specific treatment pathways should be considered, as men show more calcification of the valve and women show more valvular fibrosis.

Besides non-contrast CT showing calcification of the aortic valve, PET combined with CT has been used to identify disease activity in the aortic valve. Two PET tracers,[18]F-fluorodeoxyglucose (^{18}F-FDG) and ^{18}F-sodium fluoride (^{18}F-NaF) are known to target inflammation and calcification, respectively. The uptake of ^{18}F-FDG, a glucose analogue, is increased in active metabolic cells such as vascular macrophages.[24] ^{18}F-NaF is a bone tracer used to detect calcium formation and remodelling.[25] Marincheva-Savcheva et al. evaluated the ^{18}F-FDG uptake in patients with AS compared with an age-matched control group.[26] This study demonstrated that ^{18}F-FDG uptake is increased in patients with AS. However, when subdividing the patients based on mild, moderate or severe AS, ^{18}F-FDG uptake was increased in patients with mild and moderate AS, but not in those with severe AS, suggesting that inflammation is predominant during the early phase of degenerative AS. Dweck et al. investigated the uptake of ^{18}F-FDG and ^{18}F-NaF in the aortic valves of patients with normal aortic valves and those with various grades of AS.[27] Patients with severe AS showed the highest uptake of ^{18}F-NaF and ^{18}F-FDG compared to those with normal aortic valves. Moreover, ^{18}F-NaF uptake increased progressively with advancing disease severity, whereas ^{18}F-FDG showed a more modest increase. However, the studies did not mention whether there were any sex differences in the uptake of ^{18}F-FDG and ^{18}F-NaF in patients with AS.

Imaging Sex Differences in the Phenotype of Aortic Stenosis: Diagnostic Challenges

Severe AS is diagnosed when the aortic valve shows restrictive motion of the cusps, the peak velocity of the aortic jet is >4 m/s, the mean transvalvular pressure gradient is >40 mmHg and the calculated aortic valve area (AVA) is <1 cm^2 (or ≤0.6 cm^2/m^2 when indexed for body surface area). However, this diagnosis is not always straightforward because specific geometric assumptions and the influence of the loading conditions may lead to discordant grading. Low-flow (stroke volume index ≤35 ml/m^2) low-gradient (≤40 mmHg) severe AS (AVA <1 cm^2) can be observed in as much as 40% of patients, challenging the diagnosis of severe AS. Classical low-flow low-gradient severe AS is characterised by a left ventricular ejection fraction (LVEF) <50% and is more likely to be observed in men. In contrast, women more frequently show paradoxical low-flow low-gradient severe AS, characterised by a preserved LVEF.[28]

In patients with low-flow low-gradient severe AS, it is important to distinguish true-severe AS from non-severe AS (pseudo-severe AS). Low-dose dobutamine stress echocardiography (DSE) is the first recommended modality to confirm the diagnosis of true-severe AS in patients with low-flow low-gradient severe AS.[29] True-severe AS can be considered if the AVA remains <1.0 cm^2 and the mean gradient increases to ≥40 mmHg at any flow rate.[30] Patients with classical low-flow low-gradient AS can fail to show an increase in stroke volume ≥20% during DSE. In these patients, the severity of AS cannot be accurately determined with DSE. The uncertainty of the diagnosis of severe AS also remains in patients with a significant increase in stroke volume but with small AVA and low gradient. In these patients, projected AVA at a normal flow rate is useful to grade the AS severity.[31] A projected AVA <1.0 cm^2 is considered as true-severe AS. This calculation is only feasible if there is an increase of ≥15% in mean transvalvular flow rate.

In patients with paradoxical low-flow low-gradient AS it is important to first identify whether there is an underlying cause of the low flow. If there is no underlying cause, then beside low-dose DSE, exercise-stress echocardiography can be used to determine the true severity of AS.[32]

However – as mentioned above – in some patients, the true severity of AS cannot be determined with DSE. In these patients, the severity of AS can be assessed with CT using the AVC score. In 646 patients with preserved LVEF and moderate and severe AS Clavel et al. showed different thresholds of AVC in men and women to define severe AS: 1,274 AU in women and 2,065 AU in men.[33] These results were confirmed in a multicentre registry by Pawade et al. including 918 patients with at least mild AS and CT.[34] The AVC threshold was 1,377 AU for women and 2,062 AU for men. These results led to the inclusion of AVC assessed with CT to refine the diagnosis of severe AS and using specific sex-specific cut-off values of AVC (Agatston score >1,200 AU in women and >2,000 AU in men).[3]

In addition, assessment of the acceleration time (AT) to ejection time (ET) ratio may help to assess the AS severity in these patients.[35,36] Altes et al. evaluated the association between the AT/ET ratio and AS severity in 365 patients with low-gradient severe AS and preserved LVEF.[36] An AT/ET ratio of >0.36 was an independent predictor of mortality in these patients. Einarsen et al. evaluated the association between increased AT/ET ratio and prognosis in 1,530 asymptomatic patients with mild-moderate AS and low-gradient severe AS.[35] In the total study population, an AT/ET ratio ≥0.32 was significantly associated with a higher risk of cardiovascular death and heart failure hospitalisation. In patients with moderate AS, an AT/ET ratio of >0.37 was the optimal cut-off point to identify the patients at risk. However, it is important to note that the AT/ET ratio was not useful in the discrimination of women at risk of presenting all-cause death, cardiovascular death and heart failure hospitalisation. Therefore, we cannot conclude that this parameter will be useful in the decision making

for women with low-gradient severe AS.

## Imaging Sex Differences in the Aortic Root in Aortic Stenosis

Sex differences in the dimensions of the aortic root and ascending aorta are well-known. Accordingly, current guidelines recommend indexing the different segments of the aortic root and ascending aorta.[37] Women have a smaller aortic valve annulus than men, which has an impact on the diagnosis of aortic stenosis severity.[38,39] Smaller aortic valve annulus diameters lead to smaller AVA calculated by the continuity equation. In the SEAS trial population, indexing the AVA for body surface area increased the prevalence of severe AS from 31% to 44%.[39] Interestingly, the increment in the prevalence of severe AS was more pronounced among men (from 23% to 42%; p<0.001) compared with women (from 43% to 46%; p=not significant). From the therapeutic point of view, a small aortic annulus has been associated with less favourable valve haemodynamics after aortic valve replacement (AVR), particularly when the AVR is performed surgically.[38] Among 7,864 consecutive patients with severe AS undergoing AVR, 944 had an aortic valve annulus diameter ≤21 mm on transthoracic echocardiography, with 80% of them being female.[38] After AVR, the mean transvalvular gradient and the rates of prosthesis–patient mismatch were significantly lower among those treated with transcatheter AVR compared with those treated with surgical AVR (12 ± 7 mmHg versus 15 ± 6 mmHg; p<0.001 and 14% versus 24%; p=0.001, respectively).

Furthermore, a smaller ascending aorta in women versus men has also diagnostic implications. A small ascending aorta is associated with a more pronounced pressure recovery phenomenon, not taken into consideration in the continuity equation. By correcting the AVA by the aortic area measured at the level of the sinotubular junction, the energy loss index is calculated. The energy loss index more accurately reflects the severity of AS.[40,41] In the SEAS trial, patients with a small aortic root, defined by a diameter of the sinotubular junction indexed for body height of <1.4 cm/m in women and <1.5 cm/m in men, had more severe AS defined by AVA or indexed AVA but less severe when the energy loss index was used.[42] A small aortic root was associated with the female sex and higher pressure recovery and lower LV mass index among other parameters. These studies were performed using echocardiography to assess the dimensions of the aortic root. However, it is well-known that CMR and CT have better spatial resolution to assess the dimensions of these structures.

## Imaging Sex Differences in Left Ventricular Remodelling in Aortic Stenosis

The LV pressure overload caused by AS leads to LV hypertrophy to maintain normal wall stress and preserved LV systolic function. However, excessive LV hypertrophy can eventually lead to myocardial oxygen supply–demand mismatch and myocardial fibrosis that can lead to LV dysfunction.[43] Similar to the structural changes that occur in the aortic valve, the LV responds to the pressure overload differently in women and men. Echocardiographic studies have shown that men demonstrate more LV systolic dysfunction and larger LV mass and LV volumes while women more often show preserved LVEF, smaller LV mass and LV volumes.[6,44,45] Based on the LV relative wall thickness and the LV mass, four different patterns of LV remodelling have been described. Among patients with AS, men more often show concentric and eccentric hypertrophy, whereas women more often show normal LV patterns of concentric remodelling (*Figure 2*).[46] In particular, LV concentric hypertrophy and concentric remodelling have been associated with smaller stroke volume index and low-flow low-gradient severe AS. Lower stroke volume index (lower flow) has been associated with poor outcomes and sex-specific thresholds

Figure 1: Calcific Aortic Stenosis in Men and Women Assessed with Contrast-enhanced CT

Short-axis view of the aortic valve of a female patient aged 82 years (A) and a male patient aged 81 years (B) with severe aortic stenosis. The calcification burden is larger in the male patient, whereas the fibrotic component is larger in the female patient.

Figure 2: Echocardiographic Assessment of the Left Ventricular Remodelling Pattern in Severe Aortic Stenosis


Example of a female patient with severe aortic stenosis and concentric hypertrophy. A: parasternal long-axis view of the left ventricle and aortic valve, showing thickened cusps of the aortic valve and severely hypertrophied left ventricular septum and posterior wall; B: short-axis view of the aortic valve with limited opening of the aortic valve; C: short-axis view of the mid-ventricular level showing concentric hypertrophy.

have been proposed: <40 ml/m² for men and <32 ml/m² for women.[47] Furthermore, LV concentric hypertrophy is associated with a higher degree of myocyte apoptosis and replacement fibrosis, which is strongly associated with poor outcomes.[48–50] The association between the type of LV remodelling and outcomes in women with severe AS and preserved LVEF differs from that observed in men: LV concentric hypertrophy was associated with 60% increased risk of all-cause or cardiovascular mortality in women whereas there was no significant association in men.[46] These findings suggest that the structural changes that lead to LV concentric hypertrophy may be different for men and women and cannot be characterised with echocardiography alone.

## CT

Contrast-enhanced CT can also be used for characterisation of LV remodelling in response to severe AS.[10] This 3D imaging technique provides high spatial resolution images to assess LV mass and volumes. Furthermore, novel technologies allow the assessment of the extracellular volume as a measure of myocardial fibrosis.[51] In contrast to echocardiographic studies, Kuneman et al. reported more LV concentric remodelling in men with severe AS compared with women, whereas the frequency of the other LV remodelling patterns was similar in both sexes.[10] Furthermore, there was a significant association between LV concentric hypertrophy and poor survival in men, findings that contrast with the echocardiographic study.[46] Differences in the type of patients and imaging techniques used to assess LV remodelling may explain the discrepant

Figure 3: Cardiac Magnetic Resonance to Assess Left Ventricular Remodelling in Severe Aortic Stenosis

On the cine image of the coronal view, the restrictive motion of the aortic valve cusp can be noted (A). On late gadolinium contrast-enhanced short-axis view, concentric hypertrophy can be observed with replacement fibrosis in the anterior wall (B, arrow). With T1 mapping techniques the relaxation time can be measured to estimate the extent of diffuse myocardial fibrosis (C).

Figure 4: Use of Multimodality Imaging in Women with Discordant Grading Aortic Stenosis

AS = aortic stenosis; AU = arbitrary units; AVA = aortic valve area; CTA = CT angiography; LVEF = left ventricular ejection fraction. + =- presence - = absence.

results of the studies.

LV myocardial extracellular volume can be quantified with CT using the data acquired without (baseline) and with contrast (3 minutes post-contrast pseudo equilibrium axial shuttle-mode scans).[51] Using this technique, Scully et al. showed in 112 patients with severe AS (49% men) undergoing transcatheter aortic valve implantation that a high extracellular volume (>29.7%) was associated with poor survival after intervention.[51] However, no details in terms of sex differences in extracellular volume were provided.

Cardiac Magnetic Resonance

Besides being the reference standard for quantification of cardiac chamber dimensions and function, CMR is unique for providing characterisation of myocardial tissue. Using native and post-contrast T1 mapping sequences, several measures have been proposed to estimate diffuse myocardial fibrosis. In addition, late gadolinium contrast-enhanced

(LGE) sequences provide information on myocardial replacement fibrosis (*Figure 3*). The amount of diffuse and replacement fibrosis has been associated with poor outcomes in patients with severe AS.[48,52–54] Using CMR, differences in the response of the LV to pressure overload have also been reported between sexes. Studies including only patients with severe AS have demonstrated larger myocardial replacement fibrosis in men and similar extents of extracellular volume fraction between sexes.[8,12] In the study by Singh et al., asymptomatic men with moderate and severe AS more frequently showed LV concentric remodelling and larger LGE and extracellular volume index compared with women.[8] Interestingly, LV concentric remodelling was associated with new onset of symptoms only in men, suggesting that women with severe AS show a different pattern of remodelling that cannot reduce the wall stress and filling pressures in response to AS.[8]

In contrast, among 249 patients with at least mild AS, Tastet et al. showed that there were no statistically significant differences between men and

women in terms of type of LV remodelling, although men showed a tendency to more often exhibit concentric hypertrophy.[55] In addition, men showed larger LV mass than women but women presented with larger amounts of myocardial replacement fibrosis and extracellular volume fraction (diffuse fibrosis). Interestingly Treibel et al., showed that after AVR, focal myocardial replacement fibrosis is irreversible, but diffuse fibrosis regresses.[56] These findings suggest that assessment of diffuse myocardial fibrosis may be used as a biomarker to determine the optimal timing of AVR and to monitor the response to AVR.

Clinical Implications

Challenges in the diagnosis of AS severity and the differences in the pathophysiology of AS (in terms of the degeneration process of the aortic valve and response of the LV to the pressure overload) lead to differences in the management and outcomes of men and women with severe AS. A recent large registry including 3,632 patients (42% women) with mild to moderate AS, showed that being female was associated with higher mortality and less referral to aortic valve intervention; this excess mortality was particularly observed among women with discordant grading AS.[57] Acknowledging the differences in diagnosis, characterisation of the LV remodelling response and therapeutic management is the first step in performing prospective studies focused on the diagnostic yield of imaging tests and the efficacy of therapies (from medical therapies targeting the degeneration process of the valve to interventional therapies that aim at achieving the best valve haemodynamics and the best regression of LV remodelling) for men and women with AS. These studies will have an impact on current recommendation guidelines that acknowledge the lack of robust data on sex differences in management and outcomes in AS.[3] *Figure 4* proposes a diagnostic algorithm to facilitate the diagnosis of severe AS in women with discordant grading AS and to improve the referral to effective invasive treatments. ❑

1. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease. *Eur Heart J* 2003;24:1231–43. https://doi.org/10.1016/s0195-668x(03)00201-x; PMID: 12831818.
2. Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. *Nat Rev Cardiol* 2011;8:162–72. https://doi.org/10.1038/nrcardio.2010.202; PMID: 21263455.
3. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J* 2022;43:561–632. https://doi.org/10.1093/eurheartj/ehab395; PMID: 34453165.
4. Aggarwal SR, Clavel MA, Messika-Zeitoun D, et al. Sex differences in aortic valve calcification measured by multidetector computed tomography in aortic stenosis. *Circ Cardiovasc Imaging* 2013;6:40–7. https://doi.org/10.1161/CIRCIMAGING.112.980052; PMID: 23233744.
5. Tastet L, Enriquez-Sarano M, Capoulade R, et al. Impact of aortic valve calcification and sex on hemodynamic progression and clinical outcomes in AS. *J Am Coll Cardiol* 2017;69:2096–8. https://doi.org/10.1016/j.jacc.2017.02.037; PMID: 28427584.
6. Thaden JJ, Nkomo VT, Suri RM, et al. Sex-related differences in calcific aortic stenosis: correlating clinical and echocardiographic characteristics and computed tomography aortic valve calcium score to excised aortic valve weight. *Eur Heart J* 2016;37:693–9. https://doi.org/10.1093/eurheartj/ehv560; PMID: 26508159.
7. Simard L, Cote N, Dagenais F, et al. Sex-related discordance between aortic valve calcification and hemodynamic severity of aortic stenosis: is valvular fibrosis the explanation? *Circ Res* 2017;120:681–91. https://doi.org/10.1161/CIRCRESAHA.116.309306; PMID: 27879282.
8. Singh A, Chan DCS, Greenwood JP, et al. Symptom onset in aortic stenosis: relation to sex differences in left ventricular remodeling. *JACC Cardiovasc Imaging* 2019;12:96–105. https://doi.org/10.1016/j.jcmg.2017.09.019; PMID: 29248646.
9. Linde L, Carter-Storch R, Christensen NL, et al. Sex differences in aortic valve calcification in severe aortic valve stenosis: association between computer tomography assessed calcification and valvular calcium concentrations. *Eur Heart J Cardiovasc Imaging* 2021;22:581–8. https://doi.org/10.1093/ehjci/jeaa096; PMID: 32500142.
10. Kuneman JH, Singh GK, Milhorini Pio S, et al. Sex differences in left ventricular remodelling in patients with severe aortic valve stenosis. *Eur Heart J Cardiovasc Imaging* 2022;23:781–9. https://doi.org/10.1093/ehjci/jeab174; PMID: 34468719.
11. Cramariuc D, Rieck AE, Staal EM, et al. Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS substudy). *Am J Cardiol* 2008;101:510–5. https://doi.org/10.1016/j.amjcard.2007.09.100; PMID: 18312768.
12. Treibel TA, Kozor R, Fontana M, et al. Sex dimorphism in the myocardial response to aortic stenosis. *JACC Cardiovasc Imaging* 2018;11:962–73. https://doi.org/10.1016/j.jcmg.2017.08.025; PMID: 29153564.
13. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J* 2017;38:2739–91. https://doi.org/10.1093/eurheartj/ehx391; PMID: 28886619.
14. Carabello BA, Paulus WJ. Aortic stenosis. *Lancet* 2009;373:956–66. https://doi.org/10.1016/S0140-6736(09)60211-7; PMID: 19232707.
15. Kong WK, Regeer MV, Ng AC, et al. Sex differences in phenotypes of bicuspid aortic valve and aortopathy: insights from a large multicenter, international registry. *Circ Cardiovasc Imaging* 2017;10:1-7. https://doi.org/10.1161/CIRCIMAGING.116.005155; PMID: 28251911.
16. Kong WKF, Bax JJ, Michelena HI, Delgado V. Sex differences in bicuspid aortic valve disease. *Prog Cardiovasc Dis* 2020;63:452–6. https://doi.org/10.1016/j.pcad.2020.06.004; PMID: 32599025.
17. Lindman BR, Sukul D, Dweck MR, et al. Evaluating medical therapy for calcific aortic stenosis: JACC state-of-the-art review. *J Am Coll Cardiol* 2021;78:2354–76. https://doi.org/10.1016/j.jacc.2021.09.1367; PMID: 34857095.
18. Myasoedova VA, Di Minno A, Songia P, et al. Sex-specific differences in age-related aortic valve calcium load: a systematic review and meta-analysis. *Ageing Res Rev* 2020;61:101077. https://doi.org/10.1016/j.arr.2020.101077; PMID: 32334093.
19. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. *J Am Coll Cardiol* 1997;29:630–4. https://doi.org/10.1016/s0735-1097(96)00563-3; PMID: 9060903.
20. Yan AT, Koh M, Chan KK, et al. Association Between cardiovascular risk factors and aortic stenosis: the CANHEART aortic stenosis study. *J Am Coll Cardiol* 2017;69:1523–32. https://doi.org/10.1016/j.jacc.2017.01.025; PMID: 28335833.
21. Diederichsen A, Lindholt JS, Moller JE, et al. Sex differences in factors associated with progression of aortic valve calcification in the general population. *Circ Cardiovasc Imaging* 2022;15:1-11. https://doi.org/10.1161/CIRCIMAGING.121.013165; PMID: 34983195.
22. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. *Circulation* 2005;111:3316–26. https://doi.org/10.1161/CIRCULATIONAHA.104.486738; PMID: 15967862.
23. Cartlidge TR, Bing R, Kwiecinski J, et al. Contrast-enhanced computed tomography assessment of aortic stenosis. *Heart* 2021;107:1905–11. https://doi.org/10.1136/heartjnl-2020-318556; PMID: 33514522.
24. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. *J Am Coll Cardiol* 2006;48:1818–24. https://doi.org/10.1016/j.jacc.2006.05.076; PMID: 17084256.
25. Irkle A, Vesey AT, Lewis DY, et al. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. *Nat Commun* 2015;6:1-11. https://doi.org/10.1038/ncomms8495; PMID: 26151378.
26. Marincheva-Savcheva G, Subramanian S, Qadir S, et al. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis. *J Am Coll Cardiol* 2011;57:2507–15. https://doi.org/10.1016/j.jacc.2010.12.046; PMID: 21679852.
27. Dweck MR, Jones C, Joshi NV, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. *Circulation* 2012;125:76–86. https://doi.org/10.1161/CIRCULATIONAHA.111.051052; PMID: 22090163.
28. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. *Circulation* 2007;115:2856–64. https://doi.org/10.1161/CIRCULATIONAHA.106.668681; PMID: 17533183.
29. deFilippi CR, Willett DL, Brickner ME, et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. *Am J Cardiol* 1995;75:191–4. https://doi.org/10.1016/s0002-9149(00)80078-8; PMID: 7810504.
30. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. *Circulation* 2021;143:1-37. https://doi.org/10.1161/CIR.0000000000000932; PMID: 33332149.
31. Blais C, Burwash IG, Mundigler G, et al. Projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low-flow, low-gradient aortic stenosis: the multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) study. *Circulation* 2006;113:711–21. https://doi.org/10.1161/CIRCULATIONAHA.105.557678; PMID: 16461844.
32. Clavel MA, Ennezat PV, Marechaux S, et al. Stress echocardiography to assess stenosis severity and predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis and preserved LVEF. *JACC Cardiovasc Imaging* 2013;6:175–83. https://doi.org/10.1016/j.jcmg.2012.10.015; PMID: 23489531.
33. Clavel MA, Messika-Zeitoun D, Pibarot P, et al. The complex nature of discordant severe calcified aortic valve disease grading: new insights from combined doppler echocardiographic and computed tomographic study. *J Am Coll Cardiol* 2013;62:2329–38. https://doi.org/10.1016/j.jacc.2013.08.1621; PMID: 24076528.
34. Pawade T, Clavel MA, Tribouilloy C, et al. Computed tomography aortic valve calcium scoring in patients with aortic stenosis. *Circ Cardiovasc Imaging* 2018;11:https://doi.org/10.1161/CIRCIMAGING.117.007146; PMID: 29555836.
35. Einarsen E, Cramariuc D, Bahlmann E, et al. Higher acceleration/ejection time ratio predicts impaired outcome in aortic valve stenosis. *Circ Cardiovasc Imaging* 2021;14:1-12. https://doi.org/10.1161/CIRCIMAGING.120.011467; PMID: 33461302.
36. Altes A, Thellier N, Bohbot Y, et al. Prognostic impact of the ratio of acceleration time to ejection time in patients with low gradient severe aortic stenosis and preserved ejection fraction. *Am J Cardiol* 2019;124:1594–600. https://doi.org/10.1016/j.amjcard.2019.07.064; PMID: 31522771.
37. Evangelista A, Flachskampf FA, Erbel R, et al. Echocardiography in aortic diseases: EAE recommendations for clinical practice. *Eur J Echocardiogr* 2010;11:645–58. https://doi.org/10.1093/ejechocard/jeq056; PMID: 20823280.
38. Guimaraes L, Voisine P, Mohammadi S, et al. Valve hemodynamics following transcatheter or surgical aortic valve replacement in patients with small aortic annulus. *Am J Cardiol* 2020;125:956–63. https://doi.org/10.1016/j.amjcard.2019.12.020; PMID: 31948662.
39. Jander N, Gohlke-Barwolf C, Bahlmann E, et al. Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis. *Heart* 2014;100:28–33. https://doi.org/10.1136/heartjnl-2013-304443; PMID: 23969478.
40. Heinrich RS, Fontaine AA, Grimes RY, et al. Experimental analysis of fluid mechanical energy losses in aortic valve stenosis: importance of pressure recovery. *Ann Biomed Eng* 1996;24:685–94. https://doi.org/10.1007/BF02684181; PMID: 8923988.

41. Garcia D, Pibarot P, Dumesnil JG, et al. Assessment of aortic valve stenosis severity: a new index based on the energy loss concept. *Circulation* 2000;101:765–71. https://doi.org/10.1161/01.cir.101.7.765; PMID: 10683350.

42. Bahlmann E, Cramariuc D, Minners J, et al. Small aortic root in aortic valve stenosis: clinical characteristics and prognostic implications. *Eur Heart J Cardiovasc Imaging* 2017;18:404–12. https://doi.org/10.1093/ehjci/jew159; PMID: 27491438.

43. Ross J, Jr. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. *J Am Coll Cardiol* 1985;5:811–26. https://doi.org/10.1016/s0735-1097(85)80418-6; PMID: 3882814.

44. Rohde LE, Zhi G, Aranki SF, et al. Gender-associated differences in left ventricular geometry in patients with aortic valve disease and effect of distinct overload subsets. *Am J Cardiol* 1997;80:475–80. https://doi.org/10.1016/s0002-9149(97)00398-6; PMID: 9285661.

45. Villari B, Campbell SE, Schneider J, et al. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. *Eur Heart J* 1995;16:1410–9. https://doi.org/10.1093/oxfordjournals.eurheartj.a060749; PMID: 8746910.

46. Capoulade R, Clavel MA, Le Ven F, et al. Impact of left ventricular remodelling patterns on outcomes in patients with aortic stenosis. *Eur Heart J Cardiovasc Imaging* 2017;18:1378–87. https://doi.org/10.1093/ehjci/jew288; PMID: 28064154.

47. Guzzetti E, Poulin A, Annabi MS, et al. Transvalvular flow, sex, and survival After valve replacement surgery in patients with severe aortic stenosis. *J Am Coll Cardiol* 2020;75:1897–909. https://doi.org/10.1016/j.jacc.2020.02.065; PMID: 32327100.

48. Weidemann F, Herrmann S, Stork S, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. *Circulation* 2009;120:577–84. https://doi.org/10.1161/CIRCULATIONAHA.108.847772; PMID: 19652094.

49. Milano AD, Faggian G, Dodonov M, et al. Prognostic value of myocardial fibrosis in patients with severe aortic valve stenosis. *J Thorac Cardiovasc Surg* 2012;144:830–7. https://doi.org/10.1016/j.jtcvs.2011.11.024; PMID: 22244555.

50. Dweck MR, Joshi S, Murigu T, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. *J Am Coll Cardiol* 2011;58:1271–9. https://doi.org/10.1016/j.jacc.2011.03.064; PMID: 21903062.

51. Scully PR, Patel KP, Klotz E, et al. Myocardial fibrosis quantified by cardiac CT predicts outcome in severe aortic stenosis after transcatheter intervention. *JACC Cardiovasc Imaging* 2022;15:542–4. https://doi.org/10.1016/j.jcmg.2021.10.016; PMID: 34922871.

52. Musa TA, Treibel TA, Vassiliou VS, et al. Myocardial scar and mortality in severe aortic stenosis. *Circulation* 2018;138:1935–47. https://doi.org/10.1161/CIRCULATIONAHA.117.032839; PMID: 30002099.

53. Kwak S, Everett RJ, Treibel TA, et al. Markers of myocardial damage predict mortality in patients with aortic stenosis. *J Am Coll Cardiol* 2021;78:545–58. https://doi.org/10.1016/j.jacc.2021.05.047; PMID: 34353531.

54. Everett RJ, Treibel TA, Fukui M, et al. Extracellular myocardial volume in patients with aortic stenosis. *J Am Coll Cardiol* 2020;75:304–16. https://doi.org/10.1016/j.jacc.2019.11.032; PMID: 31976869.

55. Tastet L, Kwiecinski J, Pibarot P, et al. Sex-related differences in the extent of myocardial fibrosis in patients with aortic valve stenosis. *JACC Cardiovasc Imaging* 2020;13:699–711. https://doi.org/10.1016/j.jcmg.2019.06.014; PMID: 31422128.

56. Treibel TA, Kozor R, Schofield R, et al. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. *J Am Coll Cardiol* 2018;71:860–71. https://doi.org/10.1016/j.jacc.2017.12.035; PMID: 29471937.

57. Bienjonetti-Boudreau D, Fleury MA, Voisine M, et al. Impact of sex on the management and outcome of aortic stenosis patients. *Eur Heart J* 2021;42:2683–91. https://doi.org/10.1093/eurheartj/ehab242; PMID: 34023890.